Futura Medical
Guildford, United Kingdom

Futura Medical is a R&D-driven small pharma with a novel proprietary transdermal delivery system, DermaSys, and a lead programme, MED3000, in development for erectile dysfunction.


Investment Perspective

Futura Medical has struck an innovative deal with Atlantis Group to market its MED3000 topical gel for erectile dysfunction throughout China and South East Asia. Atlantis, and its associated companies, will fund any registration studies and commercialisation costs in the region, with the resulting profits being split 50:50. Atlantic will also invest £2.0m in Futura Medical through £1.5m as Convertible Loan Notes and £0.5m in warrants, with a conversion price of 20p and exercise price of 22p respectively. The collaboration addresses market access to the largest target population for MED3000. Updating our model to reflect this deal, our new valuation is £181.5m, equivalent to 73.1p per share (71.3p fully diluted), from £153.8m, 60.9p a share, previously.

Market information

SymbolPrimary exchanges


Commercialisation deal for China and SE Asia
Update | 04 Mar 2021
MED3000: FDA details the scope of confirmatory study
Lighthouse | 22 Oct 2020
MED3000 on course for OTC approval in Europe and US
Update | 16 Sep 2020

Recent News

Investment and joint collaboration
04 Mar 2021
US regulatory and commercial update
08 Dec 2020
Regulatory and commercial update for MED3000
22 Oct 2020
H120 interim results
16 Sep 2020